Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiebish, Michael A., Tekumalla, Poornima, Ravipaty, Shobha, Dobi, Albert, Srivastava, Shiv, Wu, Wenfang, Patil, Saurabh, Friss, Tracey, Klotz, Allison, Srinivasan, Alagarsamy, Cullen, Jennifer, Rosner, Inger L., Ali, Amina, Laszlo, Sandra, Petrovic, Michele, Fleshner, Neil, Garren, Jeonifer, Miller, Greg, Mahaveer Chand, Nischal, Rodrigues, Leonardo O., Granger, Elder, Kellogg, Mark D., Luan, Shen, Diamandis, Eleftherios, Akmaev, Viatcheslav R., Sarangarajan, Rangaprasad, Bountra, Chas, Freedland, Stephen J., McLeod, David G., Narain, Niven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302659/
https://www.ncbi.nlm.nih.gov/pubmed/34302010
http://dx.doi.org/10.1038/s41598-021-94438-4

Ejemplares similares

Ejemplares similares